These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9409497)

  • 1. Financing the rising cost of haemophilia care at a large comprehensive care centre.
    Miners AH; Sabin CA; Stevens AJ; Tolley KH; Lee CA
    J R Coll Physicians Lond; 1997; 31(6):640-4. PubMed ID: 9409497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.
    Nerich V; Tissot E; Faradji A; Demesmay K; Bertrand MA; Lorenzini JL; Briquel ME; Pouzol P; Woronoff-Lemsi MC
    Pharm World Sci; 2008 Jun; 30(3):287-92. PubMed ID: 18085428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

  • 5. Participation in research: the economic advantages in a haemophilia research population.
    Wasserman J; Ullman M; Cantini M; Moynihan K; Hoots WK
    Haemophilia; 2000 Sep; 6(5):571-4. PubMed ID: 11012704
    [No Abstract]   [Full Text] [Related]  

  • 6. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS).
    Globe DR; Curtis RG; Koerper MA;
    Haemophilia; 2004 Mar; 10 Suppl 1():63-70. PubMed ID: 14987251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors.
    Ullman M; Hoots WK
    Haemophilia; 2006 Dec; 12 Suppl 6():74-9; discussion 79-80. PubMed ID: 17123398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemophilia treatment in the United Kingdom from 1969 to 1974.
    Biggs R
    Br J Haematol; 1977 Apr; 35(4):487-504. PubMed ID: 871406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom.
    Rizza CR; Spooner RJ
    Br Med J (Clin Res Ed); 1983 Mar; 286(6369):929-33. PubMed ID: 6403138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
    Roosendaal G; Lafeber FP
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemophilia.
    Cahill MR; Colvin BT
    Postgrad Med J; 1997 Apr; 73(858):201-6. PubMed ID: 9156121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will recent innovations in therapy save perceived deficiencies in self-sufficiency policies.
    Limentani SA
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 4():S81-4. PubMed ID: 7795145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
    Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML
    Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994.
    Miners AH; Sabin CA; Tolley KH; Lee CA
    Haemophilia; 1998 Jan; 4(1):4-9. PubMed ID: 9873858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].
    Briët E; Mauser-Bunschoten EP
    Ned Tijdschr Geneeskd; 1997 Dec; 141(52):2566-71. PubMed ID: 9555158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financial aspects of haemophilia care in Puerto Rico and other Latin American countries.
    Santiago-Borrero PJ; Ortiz I; Rivera-Caragol E; Maldonado NI
    Haemophilia; 1999 Nov; 5(6):386-91. PubMed ID: 10583524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The economic impact of factor VIII inhibitors in patients with haemophilia.
    Bohn RL; Aledort LM; Putnam KG; Ewenstein BM; Mogun H; Avorn J
    Haemophilia; 2004 Jan; 10(1):63-8. PubMed ID: 14962222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of severe haemophilia in Toronto.
    Heemstra HE; Zwaan T; Hemels M; Feldman BM; Blanchette V; Kern M; Einarson TR
    Haemophilia; 2005 May; 11(3):254-60. PubMed ID: 15876271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.